Abstract
Five OXA-232 carbapenemase-producing Klebsiella pneumoniae isolates, belonging to the pandemic clone sequence type 15 (ST15), were isolated from neonates and coproduced blaCTX-M-15 and blaSHV-1 genes. All isolates were resistant to ertapenem (MICs of >32 μg/ml) and meropenem (MICs of 4 to 8 μg/ml) and susceptible or intermediate to imipenem (MICs of 1 to 2 μg/ml). The blaOXA-232 gene was located on a ColE-type transformable plasmid of 6,141 bp. To the best of our knowledge, this is the first report of OXA-232 carbapenemase among clinical isolates in China.
Keywords:
Klebsiella pneumoniae; OXA-232; ST15; clonal dissemination; neonates.
Copyright © 2017 American Society for Microbiology.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Bacterial Proteins / genetics*
-
Bacterial Proteins / metabolism
-
China
-
Drug Resistance, Multiple, Bacterial / genetics*
-
Ertapenem
-
Humans
-
Imipenem / pharmacology
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology
-
Klebsiella pneumoniae / genetics*
-
Klebsiella pneumoniae / isolation & purification
-
Meropenem
-
Microbial Sensitivity Tests
-
Plasmids / genetics
-
Thienamycins / pharmacology
-
beta-Lactamases / genetics*
-
beta-Lactamases / metabolism
-
beta-Lactams / pharmacology
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Thienamycins
-
beta-Lactams
-
Imipenem
-
beta-lactamase CTX-M-15
-
beta-lactamase PIT-2
-
beta-Lactamases
-
beta-lactamase OXA-232, Klebsiella pneumoniae
-
carbapenemase
-
Meropenem
-
Ertapenem